News | July 24, 2025
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
Revenue increased 11.4 per cent to Rs. 8,545 crore
Revenue increased 11.4 per cent to Rs. 8,545 crore
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
Annual EBITDA margin expands by 170 basis points
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
EBITDA before special items decreases to €4.08 billion (7.4%)
Scores highest PAT of Rs. 118 crore in FY25
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Bayer expects 2025 to be the most difficult year of its turnaround
Subscribe To Our Newsletter & Stay Updated
